News

During the double-blind treatment phase, rates of hypertension AEs were low for the placebo and erenumab 70- and 140-mg treatment groups, as well as during open-label erenumab treatment.

The registered dietician at Ann & Robert H. Lurie Children’s Hospital of Chicago provided commentary on the multidisciplinary efforts to tailor a patient’s diet. [WATCH TIME: 3 minutes]

Differences in response to treatment with levetiracetam (Keppra; UCB Pharma) among individuals with and without epileptiform activity who have Alzheimer disease warrant future investigations of other antiseizure medications in this population, according to study authors.

Following a study of patient experiences with telehealth in sleep medicine, the assistant professor in the division of pulmonary, critical care, and sleep medicine at the University of Washington shed light on the positive and negative aspects of its integration. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive.

Mitzi Joi Williams, MD, offered her perspectives on the patient and physician roles in MS care, the need for comprehensive care teams, resources for patients, and ongoing research.

In preclinical mouse models lacking both dystrophin and utrophin, treatment with an agent using the company's PN chemistry resulted in 100% survival at 40 weeks, setting up the therapy for this phase 1b2/a trial.

The assistant professor in the division of pulmonary, critical care, and sleep medicine at the University of Washington discussed key findings from a recent study on patient experience with telehealth encounters. [WATCH TIME: 3 minutes]

After 10-12 months of treatment, 51.2% of patients responded with a clinically meaningful reduction in drop seizures, while 25.3% of patients demonstrated a profound reduction.

Neurology News Network for the week of October 2, 2021. [WATCH TIME: 4 minutes]

Patients with Duchenne muscular dystrophy receiving the treatment had a decline in Mid-level Performance of Upper Limb scores in the phase 2 trial of the cell therapy.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 1, 2021.

The expert medical director at Roche provided detail on results from the phase 2 PASADENA study presented at the 2021 MDS Virtual Congress. [WATCH TIME: 3 minutes]

David R. Lynch, MD, PhD, professor of neurology, University of Pennsylvania Perelman School of Medicine, discussed why omaveloxolone’s recent success speaks to the progress made within the FA treatment space.

The investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital spoke to the data backing the investigational AMX0035 in the treatment of ALS. [WATCH TIME: 3 minutes]

Children and adults with migraine displayed significantly less REM sleep as a percentage of total sleep time than healthy individuals.

When used for at least 30 days, it was reported that patients with essential tremor reported improvement in tremor power following 54% of sessions.

Susana Vacas, MD, PhD, discussed a recent article that outlined postoperative neurocognitive disorders and the association with anesthesia in older adults undergoing surgery.

As the MS patient population includes more patients from the millennial generation, the founder and CEO of the Joi Life Wellness Group Multiple Sclerosis Center offered her insight on the way care differs for this generation compared with prior ones. [WATCH TIME: 4 minutes]

The registered dietician at Ann & Robert H. Lurie Children’s Hospital of Chicago discussed the variety of diets available to patients with epilepsy and how they differ from one another. [WATCH TIME: 3 minutes]

Expert clinicians offer their perspectives on the ongoing shortage of neurologists, transgender and gender-diverse individuals with migraine, artificial intelligence and neuroimaging, Student Sleep Health Week 2021, and the importance of rehabilitation therapy in multiple sclerosis.

The physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists discussed the importance of the care team for patients with MS and the role effective communication plays. [WATCH TIME: 4 minutes]

Even after excluding those who received ALS diagnosis in the 5 years prior, higher HDL and APOA1 levels were associated with a lower risk of ALS.

The study is the first to provide data from all Latin American countries, further identifying geographic-resultant limitations of access to technology and therapy for NMOSD.

Mitzi Joi Williams, MD, shares her insights about differences in treatment and approach between millennial patients and the older generations of those with MS.

Commenting on recent advances and persistent challenges for these patients, the associate professor of clinical occupational therapy at USC Keck Hospital spoke on the need to increase equity and access to care. [WATCH TIME: 6 minutes]

The multinational study uses change from baseline to week 12 in total Unified Parkinson’s Disease Rating Scale score, defined as sum of parts II and III scores, as the primary end point.

The agent had previously demonstrated positive results in a phase 2a setting, with favorable trends on modified Unified MSA Rating Scale scores across a 12-week period.